BUSINESS
Lupin: A long gestation period ahead
From a big product launch perspective, FY24 onwards is a more reasonable time period to watch for Lupin
BUSINESS
Cadila: Biosimilars, oncology portfolio hold promise for medium term
The Moraiya plant’s pending USFDA approval is crucial for Cadila’s US ambition
BUSINESS
Navin Fluorine: How good is the investment case with rising competition?
Navin Fluorine has proven credentials in the multi-step chemistry of fluorochemicals, which is getting stronger with R&D focus
BUSINESS
For chemicals, Budget 2022 is a minor reversal of import substitution policy
A reduction of duties on key chemicals to help soften raw material inflation
BUSINESS
Sun Pharma: Traction in specialty impressive
Overall, traction for specialty products for Sun Pharma got a helping hand from the leading products Ilumya, Cequa, Levulan and Absorica
BUSINESS
Laurus Labs: Diversification away from ARVs on track
The share of the Laurus antiretroviral business in total is expected to be less than 1/3rd by 2025, compared to 50 percent now as the company’s other engines of growth gain traction
BUSINESS
Dr Reddy’s: Supported by traction in limited competition products
Sales growth in North America was helped by healthy market share for the generic version of Vascepa
BUSINESS
Fed stance heightens risks for emerging markets
Pace at which US Fed intends to roll back accommodative monetary policy can unnerve markets. While upbeat wage growth signifies robust demand conditions leading to better earnings prospects, there is a high risk for valuation contraction due to lower liquidity
MONEYCONTROL-RESEARCH
Reliance Industries Q3FY22: Retail, renewables emerging as key growth anchors
Retail and digital assets are moving from strength to strength in terms of capabilities through inorganic forays, indicating that RIL would be in a vantage position to capitalize on new age businesses and normalization of consumption demand in times to come
BUSINESS
Bhansali Engineering: Margins likely to moderate further; valuation fair
Bhansali looks to step up the overall ABS capacity to 200,000 tonnes from the current 137,000 tonnes, with a capex of Rs 500 crore
BUSINESS
Hikal: Why we are closing recommendation for this stock
Environmental compliance, particularly for chemicals and pharma industry, is sacrosanct. Taking that into account, we close our Outperform rating for Hikal and would prefer to stay on the sidelines
BUSINESS
Divi’s Lab: Green chemistry can set it apart
The management of Divi's Lab asserts that there are no Nitrosamine or Azido impurities in the company's Sartan API offerings.
BUSINESS
Laurus Labs: Pick-up in fermentation opportunity a key watch
As per a recent presentation by chief business officer, Laurus Bio, Rajesh Krishnamurthy, for most of the cultivated meat manufacturers, about two-thirds of the variable cost is triggered by proteins and protein growth factors. And Laurus plans to reduce its cost through economies of scale and process innovation.
BUSINESS
At Shivalik Rasayan, pharma comes up as a big growth lever
Medicamen Biotech plans to go for domestic launch of oncology formulations from January 2022, in sync with API supply from Shivalik Rasayan. This is the key near-term trigger.
BUSINESS
Supriya Lifescience IPO: A play on lower supply-chain risk for APIs
Supriya Lifescience's key strengths include 12 products, contributing to 67 percent of sales, which are backward integrated to the level of basic chemicals
BUSINESS
Fed presses the pedal harder on taper on stronger growth
Fed chair Jerome Powell indicated that the time between the end of tapering and the first rate hike could be short. Interestingly, the rationale for that has less to do with inflation, but more to do with the strong demand environment and labour market tightness
BUSINESS
Medplus Health Services IPO: What does the investment prescription read?
Investors can wait for traction in operational performance post the listing before taking a call on investment in Medplus Health Services
BUSINESS
Galaxy Surfactants looks forward to life beyond cost inflation
Operationalisation of new plants and the overall capacity utilisation of 67 percent provide enough room to meet medium-term demand for Galaxy Surfactants
BUSINESS
IPCA Labs: Domestic beat offsets API weakness
The key near-term challenge for IPCA is with respect to API sales. The company expects a softer Q3 due to the supply disruption in Sartan APIs and elevated raw material prices
BUSINESS
Explained, the US earnings season
In 2021, earnings have accounted for the lion’s share of S&P 500's total return
BUSINESS
Tarsons Products IPO: A play on rapid growth in health care research
Going forward, research demand in Contract Research Organisations, IVF clinics and diagnostic labs is expected to lead the overall demand for Tarsons Products
BUSINESS
Navin Fluorine: Executing multi-year contract template
Navin Fluorine's recent success on new molecule/product launches stems from its in-house R&D at the Surat facility. This new deal is one of them
BUSINESS
Vidhi Specialty: Is the margin contraction a worry for the long term?
We continue to look at Vidhi as the preferred way to play the food colour theme because of its improved operational metrics
BUSINESS
Fed tapers, but no tantrum
While the “tapering” is steeper than earlier cycle of 2014, Jerome Powell emphasized its need, given that inflation this time is much higher, job openings are better and “demand is very, very strong”.
